Indian generic drugs market has posted an impressive growth pattern over the last few years. Currently, the Indian pharmaceutical market is fully dominated by generic drugs and in the near future, this scenario is likely to remain the same. The Indian pharmaceuticals market increased at a CAGR of 17.46 per cent during 2005-16 with the market increasing from US$ 6 billion in 2005 to US$ 36.7 billion in 2016 and is expected to expand at a CAGR of 15.92 per cent to US$ 55 billion by 2020. But at the same time there are immense of regulatory concerns raised by the global authorities over the the quality of drugs manufactured in India.
Keeping this in mind CPhI India brings you the 6th Edition of Global Pharma Regulatory Summit 2017 scheduled on 26-28 April in Mumbai, focusing on the clarification and interpretation to the most critical regulatory guidelines faced by the Indian Pharma companies. This three day strategic summit provides insights on the US, Europe and ROW region which are constitute to the major revenue of the top Indian pharmaceutical companies.
- Elemental and genotoxic impurities
- Refuse to receive Guideline
- European Pharmacopeia
- EMA pre authorization procedural
- Emerging marketing – LATAM, ASEAN, GCC and Japan
International Business Park, Oberoi Garden City, Goregaon East
Mumbai, Maharashtra 400063